VolitionRx Limited to Present at Conferences in the U.S. Next Week

ISNES,Belgium,March 15,2019 -- VolitionRx Limited(NYSEAMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer,Mr. Cameron Reynolds,is scheduled to present at two conferences in the U.S. next week.

During the conferences,Mr. Reynolds will outline Volition's business,clinical,regulatory and operational milestones,as well as the Company's recently announced clinical data and upcoming 2019 milestones.

Details of the conference presentations are as follows:

Conference:

ROTH Capital Partners 31st Annual Growth Stock Conference

Date:

Monday,March 18,2019

Time:

12:30 p.m. PDT

Location:

The Ritz-Carlton,Dana Point,CA

Conference:

Oppenheimer & Co.29th Annual Healthcare Conference

Date:

Wednesday,March 20,2019

Time:

3:20 p.m. PDT

Location:

Westin Grand Central,New York,NY

Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management during such conference may do so by contacting Joseph Green of Edison Advisors at JGreen@edisongroup.comor Scott Powell,Executive Vice President,at investorrelations@volitionrx.com.

About Volition

Volition is a multi-national life sciences company developing simple,easy to use,cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients,but also to improve their quality of life. The tests are based on the science of NucleosomicsTM,which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition's research and development activities are currently centered in Belgium,with additional offices in London,Texas and Singapore,as the company focuses on bringing its diagnostic products to market.

For more information about Volition,visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx

LinkedIn: https://www.linkedin.com/company/volitionrx

Facebook: https://www.facebook.com/VolitionRx/

YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address,Twitter,LinkedIn,Facebook,and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website,and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Batchelor,Volition

mediarelations@volitionrx.com

+44 (0)7557 774620

Scott Powell,Volition

investorrelations@volitionrx.com

+1 (646) 650 1351

Joseph Green,Edison Advisors

jgreen@edisongroup.com

+1 (646) 653 7030

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933,as amended,and Section 21E of the Securities Exchange Act of 1934,that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's blood-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance,if Volition fails to develop and commercialize diagnostic products,it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q,as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations,estimates and projections about Volition's business based,in part,on assumptions made by management. These statements are not guarantees of future performance and involve risks,uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release,and,except as required by law,Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Pursuant to the disclosure requirements of the NYSE MKT Company Guide Section 610(b),Volition is reporting that its audited consolidated financial statements for the fiscal year endedDecember 31,2018,included in Volition's Annual Report on Form 10-K filed with theSecurities and Exchange Commissionon March 13,2019,contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to Volition's ability to continue as a going concern. This announcement does not represent any change or amendment to Volition's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31,2018.

Nucleosomics(TM)and Nu.Q(TM) and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.

View original content:/news-releases/volitionrx-limited-to-present-at-conferences-in-the-us-next-week-300813094.html